Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Calcium carbonate, active vitamin D, and statins were used by 69.0%, 22.1%, and 31.0% of patients, respectively.Characteristics of the study population.CharacteristicAll participants (n = 213)DM group (n = 81)NonDM group (n = 132)P-valueBasic information Age (years)58 ± 1460 ± 1157 ± 150.051 Female, n (%)118 (55.4)39 (48.1)79 (59.8)0.095 PD vintage (months)48 (21 to 82)33 (17 to 62)55 (27 to 92)0.002* Dialysis modalities CAPD, n (%)72 (33.8)30 (37.0)42 (31.8)0.106 APD, n (%)122 (57.3)48 (59.3)74 (56.1) Residual renal function, n (%)122 (57.3)53 (65.4)69 (52.3)0.060 Hypertension, n (%)194 (91.1)76 (93.8)118 (89.4)0.270 Hyperlipidemia, n (%)98 (46.0)41 (50.6)57 (43.2)0.291 Calcium carbonate, n (%)147 (69.0)56 (69.1)91 (68.9)0.976 Active vitamin D, n (%)47 (22.1)13 (16.0)34 (25.8)0.097 Statins, n (%)66 (31.0)30 (37.0)36 (27.3)0.135Clinical data BMI (kg/m2)25.0 ± 4.126.3 ± 4.024.1 ± 4.0< 0.001* Systolic BP (mmHg)149.9 ± 22.4157.3 ± 20.0145.5 ± 22.8< 0.001* Diastolic BP (mmHg)85.0 ± 14.484.8 ± 12.285.1 ± 15.70.877 Pulse pressure (mmHg)47.5 ± 21.553.8 ± 17.943.7 ± 22.70.001* Aortic PWV (m/s)9.1 ± 1.79.9 ± 1.88.6 ± 1.4< 0.001*Laboratory data Peritoneal CCr (L/week)47 (38 to 55)45 (40 to 55)48 (37 to 55)0.899 Renal CCr (L/week)3 (0 to 18)7 (0 to 27)1 (0 to 18)0.035* Glucose (mg/dL)102 (92 to 124)135 (108 to 168)96 (89 to 105)< 0.001* Albumin (g/dL)3.6 (3.3 to 3.8)3.6 (3.3 to 3.8)3.6 (3.4 to 3.8)0.696 Calcium (mg/dL)9.6 ± 0.79.7 ± 0.79.6 ± 0.80.333 Phosphorus (mg/dL)5.2 ± 1.45.0 ± 1.25.3 ± 1.40.085 Calcium × phosphorus (mg2/dL2)49.9 ± 13.548.2 ± 11.851.0 ± 14.50.131 Total ALP (U/L)84 (61 to 112)87 (60 to 109)82 (61 to 114)0.658CKD: MBD biomarkers Intact PTH (pg/mL)239 (96 to 479)206 (78 to 341)259 (114 to 546)0.124 FGF23 (pg/mL)708 (199 to 2771)462 (127 to 1790)1237 (251 to 3120)0.028* α-Klotho (pg/mL)624 (384 to 903)661 (443 to 922)608 (373 to 890)0.256 Fetuin-A (µg/mL)323 (254 to 405)312 (240 to 385)328 (257 to 426)0.236Continuous variable values are presented as mean ± standard deviation and were analyzed using Student’s t-test; nonnormally distributed variable values are presented as medians and interquartile ranges and were analyzed using the Mann: Whitney U test; and categorical variables are presented as numbers (percentages) and were analyzed using the chi-squared test.DM diabetes mellitus, PD peritoneal dialysis, CAPD continuous ambulatory peritoneal dialysis, APD automated peritoneal dialysis, BMI body mass index, BP blood pressure, PWV pulse wave velocity, CCr creatinine clearance, calcium × phosphorus calcium-phosphorus product, ALP alkaline phosphatase, PTH parathyroid hormone, FGF23 fibroblast growth factor 23.*A p-value of less than 0.05 was considered statistically significant.
Source: Results. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Cross-sectional study.
Cross-sectional study
Examines a population at a particular point in time.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
In this cross-sectional study, the association of serum CKD: MBD biomarkers with aortic stiffness in PD patients with and without DM was investigated.
Source: Methods.
Patients were enrolled and baseline measurements were taken between February 2020 and May 2021.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Diabetes mellitus modifies the association between chronic kidney disease-mineral and bone disorder biomarkers and aortic stiffness in peritoneal dialysis patients
Cross-sectional study · Scientific Reports · 2024
Original publication title
Diabetes mellitus modifies the association between chronic kidney disease: mineral and bone disorder biomarkers and aortic stiffness in peritoneal dialysis patients
© The Author(s) 2024
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
This study aimed to investigate the relationship of four chronic kidney disease: mineral and bone disorder (CKD: MBD) biomarkers, including intact parathyroid hormone (PTH), fibroblast growth factor 23 (FGF23), soluble klotho, and fetuin-A, with aortic stiffness in peritoneal dialysis (PD) patients, comparing those with and without diabetes mellitus (DM). A total of 213 patients (mean age 58 ± 14 years; 81 (38.0%) patients with DM) were enrolled. Their aortic pulse wave velocity (PWV) was measured using pressure applanation tonometry, while serum intact PTH, FGF23, α-klotho, and fetuin-A levels were measured using enzyme-linked immunosorbent assay.
Overall, patients with DM had higher aortic PWV than those without (9.9 ± 1.8 vs. 8.6 ± 1.4 m/s, p < 0.001). Among the four CKD: MBD biomarkers, FGF23 levels were significantly lower in DM group (462 [127 to 1790] vs. 1237 [251 to 3120] pg/mL, p = 0.028) and log-FGF23 independently predicted aortic PWV in DM group (β: 0.61, 95% confidence interval: 0.06 to 1.16, p = 0.029 in DM group; β: 0.10, 95% confidence interval: − 0.24 to 0.45, p = 0.546 in nonDM group; interaction p = 0.016).
In conclusion, the association between FGF23 and aortic PWV was significantly modified by DM status in PD patients.
Authors’ abstract
This study aimed to investigate the relationship of four chronic kidney disease: mineral and bone disorder (CKD: MBD) biomarkers, including intact parathyroid hormone (PTH), fibroblast growth factor 23 (FGF23), soluble klotho, and fetuin-A, with aortic stiffness in peritoneal dialysis (PD) patients, comparing those with and without diabetes mellitus (DM). A total of 213 patients (mean age 58 ± 14 years; 81 (38.0%) patients with DM) were enrolled. Their aortic pulse wave velocity (PWV) was measured using pressure applanation tonometry, while serum intact PTH, FGF23, α-klotho, and fetuin-A levels were measured using enzyme-linked immunosorbent assay.
Overall, patients with DM had higher aortic PWV than those without (9.9 ± 1.8 vs. 8.6 ± 1.4 m/s, p < 0.001). Among the four CKD: MBD biomarkers, FGF23 levels were significantly lower in DM group (462 [127 to 1790] vs. 1237 [251 to 3120] pg/mL, p = 0.028) and log-FGF23 independently predicted aortic PWV in DM group (β: 0.61, 95% confidence interval: 0.06 to 1.16, p = 0.029 in DM group; β: 0.10, 95% confidence interval: − 0.24 to 0.45, p = 0.546 in nonDM group; interaction p = 0.016).
In conclusion, the association between FGF23 and aortic PWV was significantly modified by DM status in PD patients.
Publication and source details
Original title: Diabetes mellitus modifies the association between chronic kidney disease: mineral and bone disorder biomarkers and aortic stiffness in peritoneal dialysis patients
Hsiang-Jung Huang; Bang-Gee Hsu; Chih-Hsien Wang; Jen-Pi Tsai; Yi-Hsin Chen; Szu-Chun Hung; Yu-Li Lin
Scientific Reports · 2024
© The Author(s) 2024https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Buddhist Tzu Chi Medical Foundation, Hualien, TaiwanTCMF-A 106-01-09TCMF-A 106-01-09Hsu Bang-Gee Lin Yu-LiRepository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T12:52:31.576875+00:00
DOI: 10.1038/s41598-024-55364-3 · PMC10894213